caretrace.iopowered by▸healthparse
SearchCohort Builder
Tools▾
KOL FinderTerritoriesDrug Compare
AI Query
Browse▾
By stateBy specialty
Pricing
SearchCohort BuilderToolsKOL FinderTerritoriesDrug CompareAI QueryBrowseBy stateBy specialtyPricing
PROVIDER PROFILE · NPI 1730114141

Sarkis Chobanian

GastroenterologyKnoxville, TNI
CROSS-REFERENCE

Related data on other Healthparse brands

ProviderScore
OIG/SAM exclusion screening, sanctions history
© 2026 CareTrace
PricingContactPrivacyTerms
REFERRAL NETWORK

Where Sarkis Chobanian's patients come from & go

Directional shared-patient flow from Medicare claims — who sends patients to this provider (inbound) and where this provider's patients go next (outbound). 11 inbound referrers · 0 outbound destinations.

Receives referrals from
Inbound — who sends patients here
PhysicianPatientsVisits
Tec North, Llc
Ambulatory Surgical Center · Powell, TN
79102
METRO KNOXVILLE HMA LLC76182
Trevor Ingeneri
Pathology · Powell, TN
6882
Pathgroup Labs, Llc
Clinical Laboratory · Nashville, TN
43139
Terence Casey
Pathology · New Orleans, LA
40104
Joseph Freeman
Certified Registered Nurse Anesthetist (CRNA) · Knoxville, TN
2434
PARKWEST MEDICAL CENTER2362
Eurofins Diatherix Laboratories Llc
Clinical Laboratory · Huntsville, AL
1625
Catherine Hunkus
Certified Registered Nurse Anesthetist (CRNA) · Youngstown, OH
1518
Paul Googe
Pathology · Knoxville, TN
1519
HOLMAN, MELISSA1417
Refers patients to
Outbound — where patients go next
No outbound pairs above the suppression threshold.
Source: CMS Physician Shared Patient Patterns (30-day window, Medicare FFS). Direction = a beneficiary seen by the first provider, then the second, within 30 days; a proxy for referral, not a documented referral. Pairs with fewer than 11 shared beneficiaries are suppressed.
MEDICARE UTILIZATION · PART B · 2024
No data available for this provider in 2024.
PRESCRIBING · PART D · 2024
Total Rx claims
25
Beneficiaries
—
Total drug cost
$365
Distinct drugs
2
Brand share
0.0%
Top prescribed drugs
Pantoprazole Sodium13 claims
Omeprazole12 claims
QUALITY · MIPS · 2024
Final MIPS score
90.7
Quality
91.5
Cost
77.6
Improvement activities
40.0
Promoting interop.
100.0
Payment adjustment
0.66%
Group
INDUSTRY PAYMENTS · OPEN PAYMENTS · 2024
No data available for this provider in 2024.